Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 6Urinary Bladder Neoplasms 2Recurrence 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Penile Neoplasms 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neuroendocrine Tumors 1Lymphoma 1Head and Neck Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Brain Neoplasms 1Anus Neoplasms 1Anatomic Stage III Breast Cancer AJCC v8 1

Interventions

Radiosurgery 50Magnetic Resonance Spectroscopy 34Temozolomide 28Bevacizumab 24pembrolizumab 23Radiotherapy 20Nivolumab 20Specimen Handling 14Ipilimumab 13Cyclophosphamide 13Mental Status and Dementia Tests 12Carboplatin 12abemaciclib 10Radiation 10trastuzumab deruxtecan 8Proton Therapy 7Pemetrexed 7Memantine 7Blood Specimen Collection 7fluciclovine F-18 6binimetinib 6Paclitaxel 6Lomustine 6Etoposide 6Cisplatin 6Capecitabine 6encorafenib 5Trastuzumab 5Surveys and Questionnaires 5Surgical Procedures, Operative 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brain Neoplasms × entinostat × 1 year × Clear all
NCT04631029 2025-10-03

Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread

National Cancer Institute (NCI)

Phase 1 Completed
3 enrolled 12 charts
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡